169750-88-3

Basic information

• Product Name: 1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid
• Synonyms: 1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid;tert-butyl octahydro-1H-pyrrolo[2,3-c]pyridine-1- carboxylate
• CAS NO: 169750-88-3
• Molecular Formula: C₁₂H₂₂N₂O₂
• Molecular Weight: 162
• Mol File: 169750-88-3.mol

Chemical Properties

• Boiling Point: 313.8±15.0 °C(Predicted)
• Appearance: /
• Density: 1.052±0.06 g/cm3(Predicted)
• PKA: 10.74±0.20(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid(169750-88-3)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid(169750-88-3)

Safety Data

• Hazardous Substances Data: 169750-88-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid is used as a building block for the synthesis of pharmaceutical compounds, due to its versatile structure and potential applications in drug discovery and development.
Used in Agrochemical Industry:
1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid is used as a building block for the synthesis of agrochemicals, contributing to the development of new and effective products in this field.
Used in Organic Synthesis:
1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid is used as a versatile intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds.
Used in Medicinal Chemistry:
1H-Pyrrolo[2,3-c]pyridine-1-carboxylic acid is used as a precursor in the preparation of various bioactive molecules, including potential anticancer and antiviral agents, due to its unique structure and properties.

Upstream product

• 370880-82-3 tert-butyl 1H-pyrrolo [2,3-c]pyridine-1-carboxylate 
• 271-29-4 6-azaindole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 949559-11-9 (3aR,7aS)-tert-butyl octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 1438072-83-3 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(1-methylhexahydro-1H-pyrrolo[2,3-c]pyridin-6(2H)-yl)propoxy)quinazolin-4-amine 
• 1438072-77-5 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydro-1H-pyrrolo[2,3-c]pyridin-6(2H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438081-00-5 tert-butyl 6-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)octahydro-1H-pyrrolo[2,3-c] pyridine-1-carboxylate 
• 1374240-00-2 1-((3aS,7aS)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374240-01-3 1-((3aR,7aR)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374243-45-4 C₂₆H₃₅Cl₂N₇O₂Si 
• 1374239-83-4 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374239-82-3 2-(3,5-dichlorophenylamino)-1-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-octahydro-1H-pyrrolo[2,3-c]pyridin-6-yl]ethanone 
• 1374243-70-5 C₁₅H₁₉Cl₂N₃O 
• 1374243-44-3 tert-butyl 6-(2-(3,5-dichlorophenylamino)acetyl)octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 1350916-85-6 N-[3-fluoro-2-(octahydro-6H-pyrrolo[2,3-c]pyridin-6-yl)phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide 
• 1350918-43-2 tert-butyl 6-(2-fluoro-6-(4-(2-methylpyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxamido)phenyl)octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 1350918-42-1 tert-butyl 6-(2-amino-6-fluorophenyl)octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 

Relevant articles and documents

QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.

PYRROLOPYRIDINES AS KINASE INHIBITORS

Compounds of Formula (I) are useful for inhibition of CHKl and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.